Algert Global LLC cut its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 67.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,554 shares of the company's stock after selling 26,494 shares during the period. Algert Global LLC's holdings in TransMedics Group were worth $783,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Atlas Capital Advisors Inc. purchased a new stake in shares of TransMedics Group in the fourth quarter worth about $31,000. Hager Investment Management Services LLC acquired a new position in shares of TransMedics Group in the 4th quarter valued at $33,000. Sachetta LLC purchased a new stake in TransMedics Group during the fourth quarter worth $40,000. AlphaQuest LLC acquired a new stake in TransMedics Group during the fourth quarter valued at $52,000. Finally, Arcadia Investment Management Corp MI purchased a new position in TransMedics Group in the fourth quarter valued at $72,000. Institutional investors and hedge funds own 99.67% of the company's stock.
Wall Street Analysts Forecast Growth
TMDX has been the topic of a number of analyst reports. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Oppenheimer upped their target price on TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a research note on Friday. Piper Sandler reissued an "overweight" rating and issued a $125.00 price target (up previously from $105.00) on shares of TransMedics Group in a research note on Friday. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, TransMedics Group presently has a consensus rating of "Moderate Buy" and a consensus price target of $126.70.
Check Out Our Latest Stock Analysis on TMDX
TransMedics Group Stock Performance
NASDAQ:TMDX opened at $111.50 on Friday. The stock has a market capitalization of $3.77 billion, a P/E ratio of 118.62 and a beta of 1.91. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a 50 day moving average price of $78.53 and a 200 day moving average price of $75.42.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.41. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. During the same quarter in the previous year, the business earned $0.35 EPS. The company's quarterly revenue was up 48.2% compared to the same quarter last year. Equities research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.
TransMedics Group Profile
(
Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TransMedics Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.
While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
